Akanda Corp.

AKAN Healthcare Drug Manufacturers Specialty & Generic

Akanda Corp.’s revenue for fiscal 2025 (year ended December 2025) was $258,100.00, down 69.2% from fiscal 2024. Insiders bought in the last twelve months.

1.20 0.11 −8.40%
Market cap
$3.5M
P/E
—
Fwd P/E
—
Dividend yield
—
F-score
1/9
Altman Z
−26.39
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Jan '22 Dec '21 Jan '21 Dec '20 Jan '20 Jan '19
Piotroski F-Score
1 6 2 6 — 5 — — — —
Altman Z-Score
(26.39) (11.25) (10.81) (2.36) — — — — — —
P/S ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Altman Z″-Score (non-manufacturers)
(63.09) (24.68) (28.99) (3.83) — (11.25) — (11.12) (13.55) —
Beneish M-Score
— (0.76) (1.04) 52.90 — — — — — —
P/Operating CF
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
P/B ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
EV/Sales
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
EV/FCF
(0.68) 0.08 (0.17) (0.11) 0.00 0.00 0.00 0.00 0.00 —
Current Ratio
0.58 1.39 0.18 0.41 0.41 0.48 0.48 0.05 0.05 —
Net Debt/EBITDA
(2.75) 0.96 6.03 (0.19) (0.19) (2.49) (2.69) (6.23) (6.71) 0.00
Debt/Equity
(1.08) 0.08 (1.01) 0.14 0.15 (4.15) (4.35) (1.76) (1.81) —
ROE
1,183.68% (1,830.21%) (279.79%) (94.40%) 0.00% 224.83% 0.00% 45.72% 0.00% 0.00%
ROA
(647.13%) (48.90%) (134.94%) (49.56%) 0.00% (131.99%) 0.00% (53.82%) (107.64%) 0.00%
ROIC
(624.17%) (319.90%) 0.00% (41.94%) 0.00% (46.82%) 0.00% (27.44%) 0.00% —
Return on Tangible Assets
19,720.95% (109.01%) 552.03% (175.76%) (167.57%) 340.16% 1,688.72% 235.26% (188.28%) 0.00%
Average Days of Receivables
1,979.85 358.63 245.09 172.15 172.15 2,137.10 2,137.10 0.00 0.00 —
Free Cash Flow Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% —
Free Cash Flow per Share
(115.57) (410.71) (1,739.62) (23,560.60) (3.31) (2,459.86) (2.27) (8,958.00) (0.47) (0.22)
Book value per Share
(174.03) 288.95 (4,786.12) 53,800.40 7.77 (759.10) (0.76) (25,159.50) (1.74) 0.00
Free Cash Flow
(7.96) (6.08) (1.39) (11.78) (11.47) (7.13) (6.56) (1.79) (1.35) (0.64)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026